Fresenius SE & Co. KGaA (ETR: FRE)

Germany flag Germany · Delayed Price · Currency is EUR
32.98
+0.77 (2.39%)
Nov 21, 2024, 2:10 PM CET
20.72%
Market Cap 18.14B
Revenue (ttm) 22.81B
Net Income (ttm) -383.00M
Shares Out 563.24M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE 9.56
Dividend n/a
Ex-Dividend Date n/a
Volume 392,821
Open 32.38
Previous Close 32.21
Day's Range 32.38 - 33.00
52-Week Range 24.32 - 36.24
Beta 1.07
Analysts n/a
Price Target n/a
Earnings Date Nov 6, 2024

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patie... [Read more]

Sector Healthcare
Founded 1912
Employees 193,865
Stock Exchange Deutsche Börse Xetra
Ticker Symbol FRE
Full Company Profile

Financial Performance

Financial Statements

News

Fresenius SE Raises Guidance After Strong Kabi, Helios Performances

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.

15 days ago - The Wall Street Journal

Fresenius SE Raises Guidance After Strong Kabi, Helios Performances

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.

15 days ago - WSJ

Fresenius SE & Co. reports Q3 results

15 days ago - Seeking Alpha

Fresenius: Showing Signs Of Recovery, We Have Dawn

Fresenius is showing early signs of recovery, with improved profitability and simplified structure. Read why FSNUF stock remains a Buy for long-term investors.

2 months ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2024 Earnings Conference Call July 31, 2024 7:30 AM ET Company Participants Markus Georgi - Head of Investor Relations. Michael Sen - Chief Executive Officer S...

4 months ago - Seeking Alpha

Fresenius: It's Darkest Before The Dawn

Fresenius, a German healthcare company, has the potential for significant growth and a near-term turnaround. The company is in the midst of a restructuring and has met its revenue and earnings targets...

7 months ago - Seeking Alpha

Fresenius SE: Hoping For The Turnaround In 2024

Fresenius reported mediocre results and suspended the dividend this year, but management is optimistic for fiscal 2024. The company will focus on reducing debt levels in 2024 and the deconsolidation o...

9 months ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript

Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Healthcare group Fresenius tops Q4 operating profit expectations

Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at...

9 months ago - Reuters

Fresenius perfectly positioned to combat health inequality, says CEO

Michael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.

11 months ago - CNBC International TV

Fresenius SE & Co. KGaA (FSNUF) Q2 2023 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2023 Earnings Conference Call November 2, 2023 12:00 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Michael Sen - Chief...

1 year ago - Seeking Alpha

Fresenius to assess whether state aid impacts bonus, dividend payouts

German healthcare group Fresenius said it was examining whether the state aid it received to help offset high energy costs at its hospitals business would bar it from making management bonus and divid...

1 year ago - Reuters

Fresenius SE Probably Found Its Bottom

Fresenius SE outperformed the S&P 500 in the last few quarters and could have found its temporary bottom. While the quarterly results are still not great, Fresenius Kabi is expected to grow with a hig...

1 year ago - Seeking Alpha

Fresenius: 90%+ Upside At This Time

Fresenius, a German healthcare company, is highlighted as a promising investment due to its global presence, market leadership, and potential for significant growth in the coming years. Despite underp...

1 year ago - Seeking Alpha

Fresenius launches biosimilar version of AbbVie's Humira at 5% discount

The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price...

1 year ago - Reuters

Fresenius: Still Struggling, Still Undervalued

Fresenius: Still Struggling, Still Undervalued.

1 year ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q4 2022 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q4 2022 Results Conference Call February 22, 2023 7:30 AM ET Company Participants Markus Georgi - Senior Vice President-Investor Relations Michael Sen - Chief Exe...

1 year ago - Seeking Alpha

Germany's Fresenius to simplify structure, flags potential profit fall

German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the ...

1 year ago - Reuters

Fresenius: One-Off Special Situation Opportunity To Buy

Over the last six months, Fresenius has seen the exit of its CEO, increasing activist exposure, and is reviewing the deconsolidation of its largest subsidiary Fresenius Medical Care. We view this deco...

1 year ago - Seeking Alpha

Fresenius: Maximum Pessimism Reached, Potential Triple-Digit 3-Year Rate Of Return

I've been buying Fresenius in small portions and adding to my position again and again over the past year. It's now more than 3% of my portfolio. While this company remains a long-term turnaround play...

2 years ago - Seeking Alpha

Fresenius SE: A Buy After Quarterly Results

Fresenius SE is reporting mediocre results once again with Fresenius Medical Care struggling due to labor shortage and macroeconomic challenges. While Fresenius Medical Care and Fresenius Kabi are str...

2 years ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q3 2022 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael Sen – Chief Exe...

2 years ago - Seeking Alpha

Fresenius - No One Likes A Contrarian During A Downturn

I've received plenty of inquiries with regards to Fresenius and its somewhat terrible performance YTD so far. Readers are asking if I'm "out" the company, or if I continue to believe that this company...

2 years ago - Seeking Alpha